← All trials
NCT00002633
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 1995
- Primary completion
- Dec 1, 2010
- Completion date
- Jan 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 361
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Canadian Cancer Trials GroupLead sponsor
- Velindre NHS TrustStudy chair
- Michael Reese Hospital and Medical CenterStudy chair
- National Cancer Institute (NCI)Collaborator
- Eastern Cooperative Oncology GroupCollaborator
- Southwest Oncology GroupCollaborator
- Medical Research CouncilCollaborator
- University of PennsylvaniaStudy chair
- United States ArmyStudy chair
- University of TorontoStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.